{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hydroxyurea&page=8",
    "query": {
      "intervention": "Hydroxyurea",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 196,
    "total_pages": 20,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hydroxyurea&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hydroxyurea&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T12:42:40.818Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00056433",
      "title": "Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sickle Cell Anemia"
      ],
      "interventions": [
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "L-Arginine",
          "type": "DRUG"
        },
        {
          "name": "Sildenafil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2003-03-10",
      "completion_date": "2006-12-27",
      "has_results": false,
      "last_update_posted_date": "2019-11-22",
      "last_synced_at": "2026-10-17T12:42:40.818Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00056433"
    },
    {
      "nct_id": "NCT07177300",
      "title": "Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Sickle Cell Anemia (HbSS)",
        "Sickle-β0-thalassemia (HbSβ0)"
      ],
      "interventions": [
        {
          "name": "PK-optimized oral hydroxyurea at MTD until 15 years of age.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 50,
      "start_date": "2024-12-19",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2025-09-16",
      "last_synced_at": "2026-10-17T12:42:40.818Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07177300"
    },
    {
      "nct_id": "NCT06439082",
      "title": "A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Crizanlizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "12 Years to 100 Years"
      },
      "enrollment_count": 354,
      "start_date": "2024-10-24",
      "completion_date": "2030-07-29",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-10-17T12:42:40.818Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06439082"
    },
    {
      "nct_id": "NCT05405114",
      "title": "Research Study Investigating How Well NDec Works in People With Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "NDec - oral decitabine-tetrahydrouridine",
          "type": "DRUG"
        },
        {
          "name": "HU - Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2022-07-07",
      "completion_date": "2025-07-24",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-10-17T12:42:40.818Z",
      "location_count": 53,
      "location_summary": "Mobile, Alabama • Los Angeles, California • Oakland, California + 37 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05405114"
    },
    {
      "nct_id": "NCT02088541",
      "title": "Selinexor (KPT-330) in Older Patients With Relapsed AML",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)"
      ],
      "interventions": [
        {
          "name": "Selinexor",
          "type": "DRUG"
        },
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Ara-C",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Karyopharm Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 317,
      "start_date": "2014-03",
      "completion_date": "2018-01-08",
      "has_results": true,
      "last_update_posted_date": "2023-01-26",
      "last_synced_at": "2026-10-17T12:42:40.818Z",
      "location_count": 26,
      "location_summary": "Los Angeles, California • Sacramento, California • Stanford, California + 20 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02088541"
    },
    {
      "nct_id": "NCT00568802",
      "title": "A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Muscular Atrophy, Spinal"
      ],
      "interventions": [
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match hydroxyurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "10 Years",
        "sex": "ALL",
        "summary": "1 Year to 10 Years"
      },
      "enrollment_count": 27,
      "start_date": "2004-01",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2019-10-02",
      "last_synced_at": "2026-10-17T12:42:40.818Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00568802"
    },
    {
      "nct_id": "NCT03013998",
      "title": "Study of Biomarker-Based Treatment of Acute Myeloid Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Previously Untreated Relapsed Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Samalizumab (BAML-16-001-S1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BI 836858 (BAML-16-001-S2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Daunorubicin (BAML-16-001-S1)",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine (BAML-16-001-S1)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S2)",
          "type": "DRUG"
        },
        {
          "name": "AG-221 (BAML-16-001-S3)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S3)",
          "type": "DRUG"
        },
        {
          "name": "Entospletinib (BAML-16-001-S4)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S4)",
          "type": "DRUG"
        },
        {
          "name": "Entospletinib (BAML-16-001-S5)",
          "type": "DRUG"
        },
        {
          "name": "Decitabine (BAML-16-001-S5)",
          "type": "DRUG"
        },
        {
          "name": "Entospletinib (BAML-16-001-S6)",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin (BAML-16-001-S6)",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine (BAML-16-001-S6)",
          "type": "DRUG"
        },
        {
          "name": "Pevonedistat (BAML-16-001-S9)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S9)",
          "type": "DRUG"
        },
        {
          "name": "AG-120 (BAML-16-001-S16)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S16)",
          "type": "DRUG"
        },
        {
          "name": "Gilteritinib (BAML-16-001-S8 Group 1)",
          "type": "DRUG"
        },
        {
          "name": "Decitabine (BAML-16-001-S8 Group 1)",
          "type": "DRUG"
        },
        {
          "name": "AZD5153 (BAML-16-001-S10)",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax (BAML-16-001-S10)",
          "type": "DRUG"
        },
        {
          "name": "TP-0903 (BAML-16-001-S14)",
          "type": "DRUG"
        },
        {
          "name": "Decitabine (BAML-16-001-S14)",
          "type": "DRUG"
        },
        {
          "name": "Decitabine (BAML-16-001-S8 Group 2)",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax (BAML-16-001-S8 Group 2)",
          "type": "DRUG"
        },
        {
          "name": "AZD5991 (BAML-16-001-S18)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S18)",
          "type": "DRUG"
        },
        {
          "name": "SNDX-5613 (BAML-16-001-S17)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S17)",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax (BAML-16-001-S17)",
          "type": "DRUG"
        },
        {
          "name": "Gilteritinib (BAML-16-001-S8 Group 2)",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax (BAML-16-001-S12 Arm A)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S12 Arm A)",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax (BAML-16-001-S12 Arm B)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S12 Arm B)",
          "type": "DRUG"
        },
        {
          "name": "ZE46-0134 (BAML-16-001-S21 Group 1)",
          "type": "DRUG"
        },
        {
          "name": "ficlatuzumab (BAML-16-001-S24)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S24)",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax (BAML-16-001-S24)",
          "type": "DRUG"
        },
        {
          "name": "ZE46-0134 (BAML-16-001-S21 Group 2)",
          "type": "DRUG"
        },
        {
          "name": "Bleximenib (BAML-16-001-S25/HO181)",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine (BAML-16-001-S25/HO181)",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin or Idarubicin (BAML-16-001-S25/HO181)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (BAML-16-001-S25/HO181)",
          "type": "DRUG"
        },
        {
          "name": "Revumenib (BAML-16-001-S26/HO177)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (BAML-16-001-S26/HO177)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Beat AML, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3000,
      "start_date": "2016-11",
      "completion_date": "2032-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-17T12:42:40.818Z",
      "location_count": 31,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03013998"
    },
    {
      "nct_id": "NCT00568698",
      "title": "A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Muscular Atrophy, Spinal"
      ],
      "interventions": [
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match hydroxyurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "2 Years",
        "sex": "ALL",
        "summary": "Up to 2 Years"
      },
      "enrollment_count": 29,
      "start_date": "2004-01",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2019-10-02",
      "last_synced_at": "2026-10-17T12:42:40.818Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00568698"
    },
    {
      "nct_id": "NCT00613132",
      "title": "Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "Gleevec, RAD001, and Hydroxyurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Annick Desjardins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2005-05",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2013-02-20",
      "last_synced_at": "2026-10-17T12:42:40.818Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00613132"
    },
    {
      "nct_id": "NCT04053764",
      "title": "Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease (SCD)"
      ],
      "interventions": [
        {
          "name": "Crizanlizuamb",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2019-12-10",
      "completion_date": "2023-03-20",
      "has_results": true,
      "last_update_posted_date": "2024-10-09",
      "last_synced_at": "2026-10-17T12:42:40.818Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Chicago, Illinois • Baton Rouge, Louisiana + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04053764"
    }
  ]
}